Cambridge Antibody Technology

Property	Value
rdf:type	Pharmaceutical company disestablished in 2007 Pharmaceutical company of England owl:NamedIndividual Company based in Cambridge Company formerly listed on the Nasdaq British company established in 1989 1989 establishment in England
rdfs:label	Cambridge Antibody Technology
owl:sameAs	dbr:Cambridge_Antibody_Technology
prov:wasDerivedFrom	http://en.wikipedia.org/wiki/Category:Pharmaceutical_companies_disestablished_in_2007 http://en.wikipedia.org/wiki/List_of_pharmaceutical_companies http://en.wikipedia.org/wiki/Category:Pharmaceutical_companies_of_England http://en.wikipedia.org/wiki/Category:Companies_based_in_Cambridge http://en.wikipedia.org/wiki/Category:Companies_formerly_listed_on_the_Nasdaq http://en.wikipedia.org/wiki/Category:British_companies_established_in_1989 http://en.wikipedia.org/wiki/Category:1989_establishments_in_England
skos:prefLabel	Cambridge Antibody Technology
skos:altLabel	Oxford Glycosciences
clgo:assets	215.98
clgo:country	United Kingdom
clgo:equity	180.97
clgo:fate	Acquired byAstraZenecain 2006; combined withMedImmunein 2007
clgo:foundedBy	David Chiswell Medical Research Council (United Kingdom) Gregory Winter John McCafferty
clgo:foundingYear	1989
clgo:industry	Health care Medication
clgo:keyPerson	David Chiswell
clgo:location	United Kingdom England Cambridgeshire Cambridge Granta Park
clgo:netIncome	25.25
clgo:numberOfEmployees	300
clgo:operatingIncome	147.25
clgo:owner	AstraZeneca
clgo:owningCompany	AstraZeneca
clgo:product	Belimumab Adalimumab
clgo:revenue	172.5
clgo:service	Monoclonal antibody
clgo:successor	MedImmune
clgo:type	Public limited company
is clgo:knownFor of	Gregory Winter Jane Osbourn

About: clgr:Cambridge_Antibody_Technology